J
Jeffrey L. Probstfield
Researcher at Baylor College of Medicine
Publications - 31
Citations - 1957
Jeffrey L. Probstfield is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Clinical trial & Erectile dysfunction. The author has an hindex of 12, co-authored 31 publications receiving 1866 citations. Previous affiliations of Jeffrey L. Probstfield include Baylor University.
Papers
More filters
Journal ArticleDOI
Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials.
TL;DR: Examining the architecture of the entire set of subgroups within a trial, analyzing similar subgroups across independent trials, and interpreting the evidence in the context of known biologic mechanisms and patient prognosis are recommended.
COMMENTARY Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Scott M. Lippman,Phyllis J. Goodman,Eric A. Klein,Howard L. Parnes,Alan R. Kristal,Regina M. Santella,Jeffrey L. Probstfield,Carol M. Moinpour,Demetrius Albanes,Philip R. Taylor,Lori M. Minasian,Ashraful Hoque,Sarah Moody Thomas,J J. Crowley,J. Michael Gaziano,Janet L. Stanford,Elise D. Cook,Neil Fleshner,Michael M. Lieber,J. Walther,Fadlo R. Khuri,Daniel D. Karp,Gary G. Schwartz,Leslie G. Ford,Charles A. Coltman +24 more
TL;DR: The design problems the SELECT investigators had to resolve in developing the trial, including the role of prostate cancer screening, the best forms and doses of the study agents, and estimation of the event (prostate cancer) rate of men on the placebo arm are discussed.
Journal ArticleDOI
Recruitment experience in clinical trials: literature summary and annotated bibliography.
TL;DR: Data-based management of recruitment is necessary and should include a comprehensive data monitoring system with strong administrative support at both central and local levels, and recruitment goals and provisions for corrective action if recruitment lags should be included.
Journal ArticleDOI
Surrogate endpoints in clinical trials: cardiovascular diseases.
TL;DR: This work discusses several problems common in trials with surrogate endpoints, most important is the effect of missing data, especially in the face of informative censoring.
Journal ArticleDOI
Racial differences in outcome and treatment effect in congestive heart failure
James Mathew,James Mathew,Janet Wittes,Frances McSherry,Frances McSherry,William O. Williford,William O. Williford,Rekha Garg,Jeffrey L. Probstfield,Salim Yusuf,Salim Yusuf +10 more
TL;DR: Race is not an independent predictor of mortality in CHF and the effect of digoxin on morbidity and mortality inCHF does not differ in blacks and whites.